ASX
Chimeric Therapeutics Limited
CHM:ASX•Healthcare
Sensitive ASX Announcement
Agreement with MD Anderson for Phase 1B CHM 0201 AML study
Published: 13/09/23, 08:18am (AEST)•4 pages